Micronics, Inc.

Micronics, Inc. specializes in in vitro diagnostic (IVD) devices, focusing primarily on blood grouping and pathogen detection. Their most common products are agglutination-based kits for ABO/Rh blood typing, such as the ABORhCard, as well as tests like the PanNAT STEC Test for identifying Shiga toxin-producing *Escherichia coli* (STEC). These devices are intended for laboratory use to aid in accurate blood typing and pathogen identification in clinical settings.

Micronics, Inc. is based in the United States. Since the company operates within the U.S., its devices are subject to FDA regulations, including the 510(k) premarket notification process and the Unique Device Identifier (UDI) system. This means their products are listed in the FDA’s regulatory databases, ensuring compliance with U.S. medical device requirements.

Micronics, Inc.’s devices are listed in the FDA’s 510(k) premarket notification database and the Unique Device Identifier (UDI) system. These registries track Class II medical devices like theirs, which require regulatory clearance before commercial distribution in the U.S. The inclusion in these databases confirms their compliance with FDA requirements.

Micronics, Inc.’s devices fall under Class II classification in the FDA’s regulatory framework. Class II devices are considered to have an acceptable level of risk and require special controls—such as the 510(k) clearance process—to ensure their safety and effectiveness. This classification applies to their ABO/Rh blood grouping kits and pathogen detection tests, which are designed for laboratory use.

The FDA’s 510(k) premarket notification process ensures that Class II devices, like those from Micronics, Inc., meet safety and performance standards by demonstrating substantial equivalence to a legally marketed predicate device. The Unique Device Identifier (UDI) system assigns a standardized code to each device to improve tracking, reduce medical errors, and enhance post-market surveillance. Both programs are mandatory for Class II IVDs to ensure traceability and regulatory compliance.